Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.
about
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsAnti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distributionEfficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesThe design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse HepatocarcinomaConsequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptomsThe biomolecular basis of adipogenic differentiation of adipose-derived stem cells.Intratumor heterogeneity and its impact on drug distribution and sensitivity.Recent advances in vascular disrupting agents in cancer therapy.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Tumor vascular infarction: prospects and challenges.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Combination of nanotechnology with vascular targeting agents for effective cancer therapy.Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment.Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.AG488 as a therapy against gliomas.Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.Inhibiting Solid Tumor Growth In Vivo by Non-Tumor-Penetrating Nanomedicine.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
P2860
Q26746067-D8625FF7-5AD0-4607-9E75-71F2D240DF84Q26774355-D386EEF2-0C44-4435-B174-BD67FCC0E81AQ26796955-95BE7F64-EFB1-426F-8C3E-401ADA6137D8Q33418555-C164901E-0A40-4EDA-800F-E4F99A603771Q35051870-84D5D85F-C92F-49CB-909E-6231869EC5E4Q35346839-8A83F32E-C057-4111-968D-7735011EE872Q35539229-966BCD9A-4ADD-4EFC-A62F-6F89D8CF4361Q37528662-2A82A0F4-D2B0-4484-82B2-16E9AA772F5AQ37641257-F15BFDF2-D16E-497B-80F2-EB1FB8CE0885Q38205365-3DD63CD3-D379-46EC-9DE8-215532DD4D7BQ38211694-BA136F83-0242-4626-9CF1-8587B91EBEDDQ38264533-C1687A5C-8547-4DD2-B40E-7AED38499F30Q38676164-AA9B5AE6-C708-4EF3-AD01-818F2DD77107Q38713930-A6206397-58B3-4CB9-B7F9-6934B37AE9EFQ39065317-3231F3C2-7C82-4400-A1AE-05DA60B44B87Q39205186-102A7AD0-1D98-47B7-B63E-72561400A107Q39368839-5630B7C9-BF71-4B5A-A388-75EF110CA922Q41093430-A7796B80-73DA-4018-A58B-F410122C5DBEQ41881241-4947004B-78CB-4EC1-9671-B68A9BD415B0Q41915916-FCE633D4-50B2-4B45-BF3E-0E056E4CEC4AQ41921173-EEDE004B-BEA9-4556-9457-338555F063C9Q42700872-2C0B9F4D-665F-4A20-B610-2C8C3435135CQ45994556-065083BD-3B91-491F-9399-96FB85993265Q48872676-20E65F3A-1270-42B4-ACF0-17437E94144AQ51746622-D76E0D91-D246-4704-95DD-3FF07878BAF7Q53259976-3C96DDA2-BF75-4B25-9BF1-B4CE1465183C
P2860
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumor delivery of chemotherapy ...... and vascular targeting agents.
@en
type
label
Tumor delivery of chemotherapy ...... and vascular targeting agents.
@en
prefLabel
Tumor delivery of chemotherapy ...... and vascular targeting agents.
@en
P2860
P356
P1476
Tumor delivery of chemotherapy ...... and vascular targeting agents.
@en
P2093
Francesca Bizzaro
Marta Cesca
P2860
P356
10.3389/FONC.2013.00259
P577
2013-10-01T00:00:00Z